NorthWest Biotherapeutics Inc (NWBO)

[dstock07734]

You might be right. Merck passed over DCVax-L because Merck can have collaboration with Mayo Clinic which has been doing extensive research on DC vaccine therapy and delivered spectacular results. If Mayo Clinic can expand the allogeneic tumor lysate pool, the cost of DC vaccine therapy should be reduced significantly. I saw Matthew Vandermast's post was liked by Tim Talomie (Vice President, Oncology Global Marketing Human Health Division at Merck), Mickey Rego (Vice President, Business Development at Veranova), and Kevin Pavelko (Research Scientist at Mayo Clinic) who coauthored the following paper. Matthew Vandermast used to be the President of Oncovir. It seems like Merck, Veranova acquired by Merck, and Mayo Clinic have connection with Oncovir. They probably bypassed NWBO to have connection with Oncovir. In sum, Merck has no interest in $NWBO and the longs are doomed. Are you happy now?

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
https://www.nature.com/articles/s41467-020-18962-z


Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma
https://clinicaltrials.gov/study/NCT03325101

Prevnar13 (Pfizer)
pembrolizumab (Merck)
Metastatic melanoma (2017–2020)
•Intratumoral DCs + pembrolizumab + Prevnar13

Sponsor Mayo Clinic
Study Start (Actual): 2017-11-15
Primary Completion (Actual): 2020-06-14
Principal Investigator:Matthew S. Block, M.D., Ph.D.,Mayo Clinic

Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT01239875

Pneumovax 23 (Merck)
Non-Hodgkin Lymphoma (2010–2019)
•Intratumoral DCs + cryosurgery + Pneumovax 23
•Intradermal DCs + Pneumovax 23

Study Start (Actual): 2010-11
Primary Completion (Actual): 2015-11-24
Study Chair:Yi Lin, M.D.,Mayo Clinic

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
https://pmc.ncbi.nlm.nih.gov/articles/PMC4288739/

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
https://www.sciencedirect.com/science/article/pii/S0006497119733825

Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Phase I/II Study of Dendritic Cell Therapy Delivered Intratumorally After Cryoablation and Anti-PD-1 Antibody (Pembrolizumab) for Patients With Non-Hodgkin Lymphoma
https://clinicaltrials.gov/study/NCT03035331

Prevnar13 (Pfizer)
pembrolizumab (Merck)
Non-Hodgkin lymphoma (2017–2022)
•Intratumoral DCs + cryosurgery + pembrolizumab + Prevnar13

Study Start (Actual): 2017-08-15
Primary Completion (Actual): 2022-01-25
Principal Investigator:Yi Lin, MD, PhD,Mayo Clinic

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
https://clinicaltrials.gov/study/NCT03942328
Study Start (Actual): 2019-09-19
Primary Completion (Estimated): 2027-08-31
Principal Investigator:Lewis R. Roberts, MD, PhD,Mayo Clinic in Rochester

Vaccine Therapy in Treating Patients With Recurrent Glioblastoma
https://clinicaltrials.gov/study/NCT03360708
Sponsor Mayo Clinic
Study Start (Actual): 2013-11-27
Primary Completion (Actual): 2021-06-02
Principal Investigator: Ian Parney,Mayo Clinic

Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
https://clinicaltrials.gov/study/NCT01957956
Study Start (Actual): 2013-11-11
Primary Completion (Actual): 2016-11-16
Principal Investigator: Ian Parney,Mayo Clinic

Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
https://academic.oup.com/noa/article/2/1/vdaa105/5897132

Phase I trial of adjuvant mature autologous dendritic cell/allogeneic tumor lysate vaccines in combination with temozolomide in newly diagnosed glioblastoma
https://academic.oup.com/noa/article/4/1/vdac089/6617567

Mill Creek Life Sciences
https://millcreekls.com/dendritic-cell-vaccine-2/

Folate Receptor Alpha Dendritic Cells (FRaDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial
https://clinicaltrials.gov/study/NCT06639074
Study Start (Actual): 2024-11-08
Primary Completion (Estimated): 2027-12-31
Study Completion (Estimated): 2027-12-31

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer (FRAPPE)
https://clinicaltrials.gov/study/NCT05920798
Study Start (Actual): 2023-09-28
Primary Completion (Estimated): 2027-07-15
Study Completion (Estimated): 2027-07-15

Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
https://clinicaltrials.gov/study/NCT02111941
Study Start (Actual): 2014-04-14
Primary Completion (Actual): 2021-07-27
Study Completion (Actual): 2021-07-27

Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients
https://www.nature.com/articles/s41467-020-18962-z